CD274 and non-small cell lung carcinoma: Here, the corresponding therapeutic product has shown benefit for the group of patients as a whole, and the complementary diagnostic test will only inform on enhanced benefits in subgroups, such as for example better response to nivolumab (Opdivo) in patients with advanced non-small cell lung cancer (NSCLC) that show higher protein levels of the immune checkpoint protein programmed death-ligand 1 (PD-L1) [4].